Overview
The prostate programme covers localised, locally advanced, and castration-resistant disease. Risk stratification uses PSA kinetics, multiparametric MRI, biopsy grade groups, and genomic testing when available.
Treatment pathways
Options include iodine-125 permanent seed brachytherapy for low-risk disease, external beam radiotherapy, androgen deprivation, and focal cryoablation for carefully selected patients. Urinary and sexual function outcomes are discussed with every plan.
Still have questions?
Reach our care team for personalized guidance on diagnosis, treatment, and insurance.
